Sandvik Mining achieves cybersecurity certification for product development processes
Achieving Maturity Level 2 certification indicates that Sandvik proactively incorporates cybersecurity into its product design, development, testing and maintenance procedures.
The IEC 62443-4-1 standard is a globally recognised benchmark for secure product development within industrial automation and control systems.
It ensures that products are crafted with cybersecurity considerations from inception, mitigating risks such as cyberattacks and data breaches throughout their life cycle.
Sandvik's "secure-by-design" philosophy embeds stringent security protocols early in the equipment and digital solutions design process, inherently reducing vulnerability to cyber threats.
This approach prioritises the protection of mining operations without impeding productivity.
Sandvik's clientele can benefit from structured and prompt responses to emerging cyber threats, maintaining the security of their equipment throughout its operational life.
Sandvik Mining president of digital mining technologies Riku Pulli said: 'We are proud to be among the first in our sector to attain IEC 62443 certification.
'This certification reduces cyber risk and operational disruption, enhances safety and regulatory compliance, strengthens supply chain resilience and provides security assurance for our customers. It emphasises our commitment to cybersecurity and is a signal of trust and readiness in an increasingly connected and threat-prone industrial environment.'
The certification encompasses processes for patch management, vulnerability handling and security updates.
This achievement positions Sandvik favourably in anticipation of upcoming cybersecurity regulations such as the EU Cyber Resilience Act, which will mandate manufacturers to ensure cybersecurity across a product's life cycle.
Sandvik is progressing towards additional certifications to further substantiate the security of its equipment and software solutions, reinforcing customer confidence in deploying Sandvik technologies.
Moreover, Sandvik Mining has introduced its AutoMine Surface Fleet solution, a system aimed at revolutionising autonomous drill rig operations.
The system is engineered to manage more than 15 Sandvik surface i-series drill rigs, enabling remote operations from any connected location, thereby enhancing flexibility and minimising downtime, especially during shift changes.
"Sandvik Mining achieves cybersecurity certification for product development processes" was originally created and published by Mining Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
33 minutes ago
- Fast Company
Incorporate green card pathways into international recruiting
[chones / Adobe Stock] The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Listen to this Article More info 0:00 / 6:21 The road to permanent residency in the United States is a major step for international entrepreneurs and professionals seeking to build lasting success in the American market. As the U.S. working-age population is projected to shrink over the next two decades without continued skilled immigration, attracting top-tier foreign professionals will be critical to the country's long-term prosperity. This is why understanding available green card pathways should be a key part of recruitment efforts. THE IMPACT THAT INTERNATIONAL PROFESSIONALS HAVE ON THE U.S. MARKET Retaining international talent directly translates into substantial economic growth and job creation in America. According to a 2022 National Foundation for American Policy report, 64% of the U.S.'s billion-dollar companies were founded or co-founded by immigrants or their children, and these companies create an average of 859 jobs each. Immigrants with advanced degrees may also be key to leveraging the critical and emerging technologies that can secure an innovative future. Of the full-time graduate students studying AI -related fields in American universities, 71% are international students. So it's clear that having a strong immigrant recruitment strategy will be vital for U.S. companies. However, the race for this talent pool is becoming fiercer. Countries like Canada, Germany, and Japan are actively implementing new initiatives to attract skilled workers, with Canada even creating specific programs to welcome U.S. H-1B visa holders and their families. To compete, companies that provide immigrant workers with pathways to green cards will have advantages in leading the research, production, and transformation of the future. Subscribe to the Daily Company's trending stories delivered to you every day SIGN UP EDUCATE INTERNATIONAL HIRES ON GREEN CARD PATHWAYS Permanent residency options have diversified to accommodate the increasing needs of foreign talent as well as the shifting financial dynamics of the world. Among these permanent residency options, certain ones stand out for their particular relevance to entrepreneurs and highly skilled professionals because they do not require employer sponsorship: the EB-1 visa for individuals of extraordinary ability and the EB-2 National Interest Waiver. These options allow self-petitioning for the application. Bypassing the traditional requirement of employer sponsorship in this way provides entrepreneurs with a seamless application process. This flexibility simplifies various immigration procedures for startup founders who need to maintain control over their business operations while pursuing permanent residency. EB-1: THE PATH FOR EXTRAORDINARY ABILITY The EB-1 immigrant visa category is the premier option for professionals who have risen to the top of their fields. Entrepreneurs and professionals with a proven track record of extraordinary ability in business, sciences, arts, education, or athletics can apply for the EB-1. Recent policy changes have expanded the interpretation of evidence requirements, making this category more accessible to innovators in critical and emerging fields, including but not limited to artificial intelligence, biotechnology, advanced computing, and space technologies. Employers often suggest the EB-1 route to candidates who have significant international recognition, particularly when hiring for leadership or highly specialized roles where retaining extraordinary talent is a strategic priority. Success in this category hinges on demonstrating sustained national or international acclaim with evidence like major awards, published material about the applicant's work, significant contributions to the field, and high remuneration. While sponsorship isn't necessary, employers can still play an important role in supporting candidates through this process by offering detailed letters attesting to the individual's extraordinary achievements, facilitating access to records of prior accomplishments, and assisting with evidence compilation to strengthen the petition. EB-2 NATIONAL INTEREST WAIVER: INNOVATION FOR AMERICA'S BENEFIT The EB-2 National Interest Waiver (NIW) is a highly sought-after opportunity for entrepreneurs and skilled professionals whose proposed work or endeavor can advance U.S. national interests. This pathway to permanent residency acknowledges that some ventures and talents are so valuable to the U.S. that they may be exempt from the traditional labor certification process. Similar to the EB-1, recent policy updates have clarified how to qualify for the NIW, particularly emphasizing contributions to critical and emerging industries and the U.S.'s global competitiveness. In a nutshell, obtaining swift approval for a NIW application depends on three key elements (or prongs, as in U.S. immigration terminology): substantial merit and national importance of the proposed endeavor, the applicant's well-positioning to advance the proposed endeavor, and the benefits of waiving the job offer requirement. In that regard, for instance, founders whose businesses focus on technological innovation, healthcare solutions, or environmental sustainability can be ideal candidates for this green card category. Employers often suggest the EB-2 NIW when candidates' work has a clear impact on national priorities—such as scientific research, advanced technology development, or public health improvements—and when they prefer to avoid the delays of labor certification. To strengthen their application, professionals should proactively gather evidence demonstrating the significance of their work, secure strong letters of recommendation from recognized experts in their field, and prepare a clear statement explaining how their expertise will benefit the United States. As we navigate through 2025, the landscape of global immigration continues to evolve. Henceforth, companies must view immigration not as a separate administrative task but as an integral component of their business key will lie in collaborating with international hires early on, meticulously documenting the process, and ensuring alignment with a talent strategy tailored to long-term business benchmarks. Those who approach immigration strategy with this comprehensive mindset will be best positioned to thrive in tomorrow's world. The super-early-rate deadline for Fast Company's Most Innovative Companies Awards is this Friday, July 25, at 11:59 p.m. PT. Apply today. ABOUT THE AUTHOR Muhammed Uzum is the founding attorney at Grape Law Firm PLLC. Read Muhammed's Executive Profile here. More Explore Topics
Business Insider
3 hours ago
- Business Insider
Ford Stock (NYSE:F) Slips as Ford Bronco Sport Raptor Breaks Cover
Legacy automaker Ford (F) has been trading on the back of its 'no boring cars' philosophy for a while now, and given what we have seen so far, it may be able to continue doing so for some time to come. In fact, the Ford Bronco Sport Raptor was recently spotted in the wild, looking anything but boring. Investors, though, were a bit less sure. They sent Ford shares sliding fractionally down in Thursday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The Ford Bronco line has already seen one refresh, reports noted, with the 2025 model year. That was noteworthy in and of itself as the vehicle only saw its debut in 2021. But now, a new version is said to be coming soon, along with some minor tweaks. This new version is the Ford Bronco Sport Raptor, and reports have already spotted it out in the wild. The biggest reason that anyone could tell this was a Sport Raptor is that the new vehicle has Raptor badges on the front doors, as well as one on the rear tailgate. There are also some cosmetic improvements like a taller ride height as well as larger fender flares. The increased ride height is actually important for one other upgrade: a new set of BFGoodrich Mud-Terrain T/A KM3 tires. These tires, reports note, are more commonly used with off-roading in mind, particularly on rocky or muddy terrain. Earnings Season Approaches With Ford set to reveal its earnings report in just six days, some are wondering if Ford's earnings report will give the stock price a lift. With earnings expected to be down against last year's figures—analysts expect $0.33 per share against the $0.47 per share seen this time last year—and revenues also expected to take a roughly 2% hit, some wonder if Ford's share price can get any kind of lift. Sadly, with numbers like those already expected, it would take a fairly big surprise to turn anything around in the short term. And while there are some signs of life from discretionary income in the consumer space, it may not be enough to give any real boost in the short term. Is Ford Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Hold consensus rating on F stock based on two Buys, 12 Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 1.97% rally in its share price over the past year, the average F price target of $10.14 per share implies 10.23% downside risk.
Associated Press
3 hours ago
- Associated Press
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul 25, 2025-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company's injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commission (EC) decision is expected later this year, and, if approved, lenacapavir will be marketed in the European Union (EU) under the trade name Yeytuo ®. The marketing authorization application (MAA) recommendation will now be reviewed by the EC as it evaluates lenacapavir as a potential new preventative strategy against HIV in all 27 EU Member States, as well as Norway, Iceland and Liechtenstein. Additionally, if approved, lenacapavir will be granted one additional year of market exclusivity in the EU as a result of the new indication. The CHMP also adopted a positive EU-Medicines for all (EU-M4all) opinion, which enables a streamlined assessment for World Health Organization (WHO) prequalification and will facilitate national regulatory evaluations in low- and lower-middle-income countries (LLMICs). 'This milestone reflects our commitment to reimagine HIV prevention in Europe and around the world,' said Dietmar Berger, MD, PhD, Chief Medical Officer at Gilead Sciences. 'Lenacapavir for PrEP has the potential to become a critical tool for public health, helping to expand prevention options for people who face the highest barriers to care.' Despite ongoing advances in HIV prevention, persistent social and economic factors including stigma and discrimination continue to cause disparities in PrEP use. In 2023, a total of 24,731 new HIV diagnoses were reported across 30 EU/European Economic Area countries—an increase of 11.8% compared with 2022. 'These positive opinions from the CHMP are an important step toward a new HIV prevention option that could help meet the diverse needs of people across Europe and aim at helping end new HIV infections by the EU target of 2030,' said Jean-Michel Molina, MD, PhD, Université Paris Cité, Professor of Infectious Diseases and Head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals. 'The opinions reflect the strength of the clinical evidence and the potential of long-acting innovations like lenacapavir to address real-world barriers to the use of PrEP. Expanding the range of PrEP options, in Europe and in countries around the world, is essential to making HIV prevention more accessible for people who need it most.' The positive opinions were supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In the PURPOSE 1 trial ( NCT04994509 ), data at the primary analysis showed that administration of twice-yearly subcutaneous lenacapavir led to zero HIV infections among 2,134 participants, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) in cisgender women in sub-Saharan Africa. In the PURPOSE 2 trial ( NCT04925752 ), there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous lenacapavir group, demonstrating 99.9% of participants did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral Truvada among a broad and geographically diverse range of cisgender men and gender-diverse people. In both trials, lenacapavir demonstrated superiority of prevention of HIV infections when compared with background HIV incidence (bHIV) and was generally well-tolerated, with no significant or new safety concerns identified . Data from both trials were published in The New England Journal of Medicine and, based in part on the trial results, in December 2024 the journal Science named lenacapavir its 2024 'Breakthrough of the Year.' Continued Global Regulatory Filings for Lenacapavir for HIV Prevention, Milestone Partnerships and Global Guidance Gilead is executing a global access strategy informed by health advocates and organizations that prioritizes speed and enables the most efficient paths for regulatory review, approval of and access to twice-yearly lenacapavir for PrEP. More information about Gilead's recently announced strategic partnership agreement with The Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as updates on Gilead's access strategies in countries and regions around the world: See Gilead press release More information about the WHO's recently announced guidelines for the use of lenacapavir for PrEP: See Gilead company statement Lenacapavir for PrEP is not approved by any regulatory authority outside of the United States. There is currently no cure for HIV or AIDS. About the PURPOSE Program Gilead's landmark PURPOSE program is the most comprehensive and diverse HIV prevention trial program ever conducted. The program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community engagement and health equity. The PURPOSE trials are evaluating the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV. The Phase 2 and 3 program, consisting of PURPOSE 1-5, is assessing the potential of lenacapavir to help a diverse range of people around the world who could benefit from PrEP. More information about the PURPOSE program, including individual trial descriptions, populations and locations, can be found at About Lenacapavir Lenacapavir is approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals. Lenacapavir is also approved in the United States to reduce the risk of sexually acquired HIV in adults and adolescents (≥35kg) who are at risk of HIV acquisition. The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes. Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV. The journal Science named lenacapavir its 2024 'Breakthrough of the Year.' U.S. Indication for Yeztugo® Yeztugo (lenacapavir) injection, 463.5 mg/1.5 mL, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Yeztugo. U.S. Important Safety Information for Yeztugo BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO IN UNDIAGNOSED HIV-1 INFECTION Contraindications Warnings and precautions Adverse reactions Drug interactions Dosage and administration About Gilead HIV For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead was recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Yeztugo (lenacapavir) (such as PURPOSE 1 and PURPOSE 2); uncertainties relating to regulatory applications and related filing and approval timelines, including regulatory applications for lenacapavir for PrEP, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir for indications currently under evaluation and, as a result, lenacapavir may never be successfully commercialized for such indications; Gilead's ability to effectively manage the access strategy relating to lenacapavir, subject to necessary regulatory approvals; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. U.S. full Prescribing Information for Truvada and Yeztugo, including Boxed Warning, are available Truvada, Truvada for PrEP, Yeztugo, Yeytuo, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company's website follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences). View source version on CONTACT: Ashleigh Koss, Media [email protected] Ross, Investors [email protected] KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: AIDS HEALTH INFECTIOUS DISEASES HOSPITALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Gilead Sciences, Inc. Copyright Business Wire 2025. PUB: 07/25/2025 03:00 AM/DISC: 07/25/2025 03:01 AM
